{"entity":{"id":"nct07589569","kind":"trial","name":"An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of HRS-7058 in pancreatic ductal adenocarcinoma, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.","summary":"An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer is a phase 2 interventional study registered as NCT07589569 by Shandong Suncadia Medicine Co., Ltd., with 92 participants planned, started 2026-06-04 and due to reach its primary completion in 2028-12. Interventions recorded: HRS-7058.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07589569","url":"https://clinicaltrials.gov/study/NCT07589569"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07589569","phase":"2","setting":"An Open, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-7058 in Patients With Locally Advanced or Metastatic Pancreatic Cancer Harboring KRAS G12C Mutations Who Have Failed Prior Systemic Therapy.","sponsor":"Shandong Suncadia Medicine Co., Ltd.","enrolled":92,"outcomes":[]},"route":"/trials/nct07589569/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}